glp-1 rebound weight gain Trajectory of the body after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine Rebound weight gain after stopping

[DOI] [PMC free article] [PubMed] [Google Scholar] 150.Knopman D.S., Amieva H., Petersen R.C., Chtelat G., Holtzman D.M., Hyman B.T., Nixon R.A., Jones D.T

How Tirzepatide Changes Your Relationship With Food Tirzepatide is a dual GLP-1 and GIP receptor agonist that slows gastric emptying and suppresses appetite-regulating hormones in your brain

and Spanish Society of Internal Medicine (SEMI)

Shares of other supplement brands, such as Nature's Sunshine Products and Herbalife, have also spiked, rising 131% and 124%, respectively, year over year

These agents, known for their dual impact on both immune modulation and metabolic improvement, offer a unique therapeutic potential in managing immune-mediated inflammatory diseases ( 3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib ( Several studies have reported an inverse relationship between BMI and therapeutic efficacy, indicating that obesity may attenuate clinical responses to biologic disease modifying anti-rheumatic drugs (bDMARDs)

The fertility implications of tirzepatide are also worth understanding, as improved metabolic health can increase fertility in women with PCOS or obesity-related anovulation